Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Strategies; Reimbursement

Set Alert for Pricing Strategies and Reimbursement

Pricing Strategies

Rivals Challenge Nintedanib In India

Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.

Launches Generic Drugs

Industry Urges Medicare Rethink On 505(b)(2) Policy

Teva, Sun and the AAM are among those urging the CMS to rescind its proposal to reimburse Part B drugs approved under section 505(b)(2) as multiple source products. The proposal would target one relatively small but growing part of Medicare Rx spending and reflects CMS’ ongoing concern with fast rising costs in the program.

Value-Added Medicines Reimbursement

Ciprofloxacin Garners No UK Concessions Despite Rises

Despite the average trade price of ciprofloxacin shooting up in September, no UK price concessions were granted by the DHSC.

Market Intelligence Pricing Strategies

UK’s CMA Investigates Essential Pharma Over Lithium

The CMA has launched an investigation into Essential Pharma regarding its lithium-based treatment, Priadel. As an interim measure, the company has been advised to continue supplying the bipolar disorder treatment to UK patients.

Pricing Strategies Compliance

US Allows Imports To Lower Drug Costs

With the aim of lowering prices and improving access to certain prescription drugs, the US FDA and HHS have decided to allow imports from Canada. To enable this, the FDA has finalized the rule allowing importation and issued accompanying guidance.

United States Policy

Moxonidine Rises Ramp Up In August

Moxonidine topped our table of Biggest Risers for the second month in a row, as UK prices that had doubled in July accelerated even more rapidly in August.

Market Intelligence Pricing Strategies
See All
UsernamePublicRestriction

Register